MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Utah Medical Products Cost of Revenue 2011-2025 | UTMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Utah Medical Products
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.2 M | 20.1 M | 18.1 M | 16.6 M | 17.4 M | 15.7 M | 15 M | 15.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.2 M | 15 M | 17.3 M |
Quarterly Cost of Revenue Utah Medical Products
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.21 M | 4.36 M | 4.17 M | - | 4.2 M | 4.15 M | 4.57 M | - | 5.15 M | 5.13 M | 4.68 M | - | 4.77 M | 5.28 M | 4.79 M | - | 4.5 M | 4.82 M | 4.02 M | - | 3.98 M | 3.84 M | 4.07 M | - | 5.12 M | 4.35 M | 3.96 M | - | 4.1 M | 3.98 M | 3.96 M | - | 3.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.28 M | 3.63 M | 4.39 M |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
8.76 M | $ 24.56 | 0.7 % | $ 1.13 B |  USA |
 |
Baxter International
BAX
|
6.65 B | $ 19.52 | 1.93 % | $ 9.96 B | USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 200.48 | -0.23 % | $ 57.7 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
8.41 M | $ 4.68 | 0.21 % | $ 94.4 M | USA |
 |
Harvard Bioscience
HBIO
|
46.2 M | $ 0.71 | -4.45 % | $ 30.1 M | USA |
 |
ICU Medical
ICUI
|
1.56 B | $ 148.28 | -0.1 % | $ 3.62 B | USA |
 |
iRhythm Technologies
IRTC
|
184 M | $ 170.21 | 0.82 % | $ 5.31 B | USA |
 |
Alcon
ALC
|
3.58 B | $ 79.15 | 0.43 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
118 M | $ 41.07 | -3.09 % | $ 1.93 B | USA |
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
2.8 M | $ 4.85 | 2.11 % | $ 26.7 K | USA |
 |
Repro Med Systems
KRMD
|
11.8 M | $ 5.8 | 0.35 % | $ 264 M | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 13.42 | 2.13 % | $ 548 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 81.36 | -0.88 % | $ 16.2 B | USA |
 |
LeMaitre Vascular
LMAT
|
69 M | $ 83.04 | -1.14 % | $ 1.86 B | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 111.73 | 2.6 % | $ 5.41 B | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 137.35 | -0.72 % | $ 7.32 B | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 80.24 | -3.89 % | $ 4.04 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 9.22 | -0.27 % | $ 190 M | USA |
 |
Merit Medical Systems
MMSI
|
713 M | $ 86.49 | -0.24 % | $ 5.04 B | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
2.72 B | $ 559.7 | 3.2 % | $ 199 B | USA |
 |
OraSure Technologies
OSUR
|
106 M | $ 2.49 | - | $ 185 M | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.23 | -7.65 % | $ 22.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
2.2 M | $ 0.36 | -7.4 % | $ 28.7 M | USA |
 |
Nephros
NEPH
|
5.83 M | $ 4.98 | -0.8 % | $ 51.7 M | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
1.55 B | $ 251.67 | -0.27 % | $ 36.8 B | USA |
 |
Envista Holdings Corporation
NVST
|
1.14 B | $ 22.07 | 0.46 % | $ 3.8 B | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 44.0 | 1.43 % | $ 145 M | USA |
 |
STAAR Surgical Company
STAA
|
74.3 M | $ 23.49 | -2.65 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
3.06 B | $ 253.98 | 0.82 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
11.9 M | $ 2.35 | -1.05 % | $ 190 M | USA |
 |
Pulse Biosciences
PLSE
|
11.9 M | $ 14.04 | -1.4 % | $ 674 M | USA |
 |
Predictive Oncology
POAI
|
826 K | - | - | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 160.09 | 1.72 % | $ 8.92 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.43 | -1.21 % | $ 2.32 B | USA |
 |
Retractable Technologies
RVP
|
34.1 M | $ 0.84 | 1.99 % | $ 25.1 M | USA |
 |
Teleflex Incorporated
TFX
|
1.34 B | $ 126.88 | 0.17 % | $ 5.94 B | USA |
 |
West Pharmaceutical Services
WST
|
1.89 B | $ 271.82 | 1.6 % | $ 19.8 B | USA |